We are live on ! Find out more
HVC

Healthcare Value Capital Portfolio holdings

AUM $50.7M
1-Year Est. Return 24.72%
This Fund
S&P 500
This Quarter Est. Return
+9.91%
1 Year Est. Return
+24.72%
3 Year Est. Return
+18.99%
5 Year Est. Return
+98.49%
10 Year Est. Return
–
AUM
$60.5M
AUM Growth
-$9.67M
Cap. Flow
-$7.48M
Cap. Flow %
-12.38%
Top 10 Hldgs %
86.75%
Holding
30
New
2
Increased
1
Reduced
3
Closed
9

Top Buys

Rank Stock Value
1
ASRT
Assertio
ASRT
+$3.75M
2
PTX
Pernix Therapeutics Holdings, Inc.
PTX
+$454K
3
ANIP icon
ANI Pharmaceuticals
ANIP
+$215K

Top Sells

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$6.36M
2
SEEL
Seelos Therapeutics, Inc. Common Stock
SEEL
+$1.43M
3
ABBV icon
AbbVie
ABBV
+$1.36M
4
ADYX
Adynxx Inc
ADYX
+$1.33M
5
AEGR
Aegerion Pharmaceuticals
AEGR
+$680K

Sector Composition

Rank Sector Weight
1 Healthcare 85.46%
2 Miscellaneous 14.54%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ANIP icon
1
ANI Pharmaceuticals
ANIP
$1.69B
$14.4M 23.89%
320,000
+5,000
+2% +$215K
AMRI
2
DELISTED
Albany Molecular Research Inc
AMRI
$7.99M 13.21%
402,400
– –
QLTI
3
DELISTED
QLT Inc
QLTI
$5.74M 9.49%
2,157,200
– –
PFE icon
4
Pfizer
PFE
$160B
$4.84M 8.01%
158,100
– –
DGX icon
5
Quest Diagnostics
DGX
$27B
$4.71M 7.79%
66,208
– –
AORT icon
6
Artivion
AORT
$1.3B
$3.99M 6.6%
370,000
– –
ASRT
7
DELISTED
Assertio
ASRT
$3.63M 6%
+3,333
New +$3.75M
AGN
8
DELISTED
Allergan plc
AGN
$3.13M 5.17%
10,000
– –
GSK icon
9
CALL
GSK
GSK
$101B
$2.02M 3.34%
40,000
-40,000
-50% -$2.04M
TWM icon
10
CALL
ProShares UltraShort Russell2000
TWM
$44M
$1.97M 3.25%
2,500
– –
TWM icon
11
ProShares UltraShort Russell2000
TWM
$44M
$1.97M 3.25%
2,500
– –
ANIP icon
12
CALL
ANI Pharmaceuticals
ANIP
$1.69B
$1.13M 1.87%
25,000
– –
CYTK icon
13
Cytokinetics
CYTK
$10.8B
$1.05M 1.73%
100,000
– –
AMRN
14
CALL
Amarin Corp
AMRN
$299M
$756K 1.25%
20,000
– –
MNKD icon
15
PUT
MannKind Corp
MNKD
$1.31B
$725K 1.2%
100,000
-140,000
-58% -$1.72M
FCSC
16
DELISTED
Fibrocell Science Inc.
FCSC
$672K 1.11%
9,851
– –
ZGNX
17
DELISTED
Zogenix, Inc.
ZGNX
$469K 0.78%
31,850
– –
PTX
18
DELISTED
Pernix Therapeutics Holdings, Inc.
PTX
$443K 0.73%
+15,000
New +$454K
SRNE
19
DELISTED
Sorrento Therapeutics, Inc.
SRNE
$436K 0.72%
50,000
– –
SEEL
20
DELISTED
Seelos Therapeutics, Inc. Common Stock
SEEL
– –
-1
Closed -$1.43M
VIRX
21
CALL
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$135K 0.22%
714
-1,429
-67% -$267K
SEEL
22
CALL
DELISTED
Seelos Therapeutics, Inc. Common Stock
SEEL
– –
0
– –
ABBV icon
23
AbbVie
ABBV
$456B
– –
-25,000
Closed -$1.36M
AZN icon
24
AstraZeneca
AZN
$255B
– –
-100,000
Closed -$6.36M
VTRS icon
25
CALL
Viatris
VTRS
$19.4B
– –
-50,000
Closed -$2.01M
1
2

Similar funds

C
Castlelake Minneapolis, Minnesota $48.5M AUM 87.77% 1-Year Est. Return
CC
Cedar Capital Barrington, Illinois $54.9M AUM 33.3% 1-Year Est. Return
FCOI
FirstMark Capital OF II New York $44.1M AUM 18.15% 1-Year Est. Return
FCOI
FirstMark Capital OF I New York $43.1M AUM 6.31% 1-Year Est. Return
BI
BCBSM Inc Eagan, Minnesota $42.4M AUM 0.4% 1-Year Est. Return
KC
Kelso & Company New York $42.3M AUM
SCIM
Spring Creek Investment Management Philadelphia, Pennsylvania $42.3M AUM 31.86% 1-Year Est. Return
MCP
Moab Capital Partners Southampton, New York $41M AUM 33.21% 1-Year Est. Return

Healthcare Value Capital's Q4 2015 Portfolio in Review

As of Q4 2015, Healthcare Value Capital held 30 positions worth $60.5M, down 14% from $70.1M the previous quarter. Its ten largest holdings account for 87% of the portfolio.

Healthcare Value Capital withdrew a net $7.48M in Q4 2015, closing 9 positions and reducing 3 holdings. Its most notable exit was AstraZeneca, an estimated $6.36M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, up from 77% a quarter earlier, followed by Miscellaneous.

Against the trend, Healthcare Value Capital opened a new position in Assertio worth $3.63M.

  • Healthcare Value Capital's largest Q4 2015 buy was Assertio: 3,333 shares worth $3.63M.
  • Healthcare Value Capital added most to ANI Pharmaceuticals in Q4 2015, an estimated $215K increase.
  • Healthcare Value Capital fully exited AstraZeneca in Q4 2015, selling an estimated $6.36M.
  • Healthcare Value Capital's ten largest holdings make up 87% of its $60.5M portfolio in Q4 2015.
  • Healthcare Value Capital opened 2 new positions and closed 9 in Q4 2015.
  • Healthcare Value Capital's portfolio value fell 14% quarter-over-quarter to $60.5M.

Based on Healthcare Value Capital's 13F filing for Q4 2015, filed 16 Feb 2016.